About us Contacts Drug interactions: 390 212
Drug search by name

Deferasirox and Repaglinide

Determining the interaction of Deferasirox and Repaglinide and the possibility of their joint administration.

Check result:
Deferasirox <> Repaglinide
Relevance: 26.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Deferasirox may increase the blood levels and effects of repaglinide. This can increase the risk of hypoglycemia (low blood sugar). Symptoms include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and fast or pounding heartbeats. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with deferasirox may increase the plasma concentrations of drugs that are substrates of CYP450 2C8. Deferasirox has been shown to be a moderate inhibitor of this isoenzyme. In healthy subjects, concomitant administration of deferasirox (30 mg/kg/day) and the CYP450 2C8 substrate repaglinide (0.5 mg) resulted in a 62% and 131% increase in repaglinide peak plasma concentration (Cmax) and systemic exposure (AUC), respectively.

MANAGEMENT: Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 2C8, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.

References
  • EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
  • "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
  • "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  • Skerjanec A, Wang J, Maren K, Rojkjaer L "Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers." J Clin Pharmacol 50 (2010): 205-13
Deferasirox

Generic Name: deferasirox

Brand name: Exjade, Jadenu, Jadenu Sprinkle

Synonyms: n.a.

Repaglinide

Generic Name: repaglinide

Brand name: Prandin

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction